London, UK. November 13th 2025 – After significant challenges over the past year in the UK medical cannabis import sector, Lyphe Dispensary have announced that a range of five Noidecs medical cannabis flower products are now back in stock, with more on the horizon over the next month and into 2026. Finally bringing patients greater access to the affordable range Lyphe established before the clampdown in October 2024.
With a severely restricted market over the past year, medication options have been limited to a handful of suppliers, but with this announcement by Lyphe Dispensary, it looks as though a wider range of products will be coming to UK dispensaries, bringing patients and doctors more affordable choices outside of the current monopoly.
The range of Noidecs currently available starts on the lower end with a Noidecs T18 and T19, with a mid-range T21 and goes up to Noidecs T23/T24. Each strain has been selected to address patient needs across varying THC profiles and terpene blends, empowering prescribers to find the most appropriate option for patients’ specific therapeutic requirements.
The full Noidecs product details are now listed on the Lyphe Dispensary formulary and available for qualifying prescriptions. Existing patients will need to log into their Lyphe Dispensary account to access the full details.
“Patients have been asking for the return of Noidecs, and we’re thrilled to be able to finally deliver,” said Karen Sharp, Managing Director at Lyphe Clinic.
“It’s been a bumpy road, but our focus has always been on improving patient choice and access while maintaining affordability and quality. The return of this popular brand, Noidecs, underlines our ongoing efforts and commitment to a sustainable and patient-first supply model.”
“In the near future, we look forward to being able to provide patients with a broader range of Noidecs treatment options, catering for patients who use non-flower-based products such as oils and vapes. But one step at a time!”
This news reflects Lyphe Dispensary’s ongoing mission to make medical cannabis treatment more diverse, affordable and accessible in the UK and Channel Islands.
All Noidecs products are cultivated with an emphasis on sustainability, consistency, and value, ensuring that patients receive fresh, high-quality medical cannabis-based products at affordable prices.
To learn more about Lyphe Dispensary you can visit lyphedispensary.com where you can find their contact details and latest news stories.
About Lyphe Dispensary
Lyphe Dispensary (formerly Dispensary Green) have been around since 2019 and is one of the UK’s leading dispensers of CBMPs (Cannabis-Based Medicinal Products), supporting patients through their treatment journey. Focused on affordability, accessibility, and clinical excellence, Lyphe Dispensary continues to expand its formulary with responsible leadership within the medical cannabis industry.
ENDS